# A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

> **NCT05584670** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sanofi** · enrollment: 542 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** SAR445877
- **DRUG:** Cetuximab
- **DRUG:** ADG126
- **DRUG:** Bevacizumab
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT05584670
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-29
- **Primary completion:** 2027-01-19
- **Final completion:** 2028-06-28
- **Target enrollment:** 542 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05584670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05584670, "A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05584670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*